Morgan Stanley analyst Patrick Wood raised the firm’s price target on DexCom (DXCM) to $89 from $82 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal
- Diabetes stocks rally after RFK comments on HHS campaign
- Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts
- Top Analyst Assigns Buy Rating to ‘Leading Innovator’ DexCom’s Stock (DXCM)